StephenEdward ForbesSpurgeonMD

Oncology • Portland, OR

Physician

Join to view full profile

Dr. Spurgeon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Spurgeon's full profile

Already have an account?

Office
3181 Sw Sam Jackson Park Rd
Portland, OR 97239
Phone+1 503-494-6101

Education & Training

Oregon Health & Science University (OHSU Health)Fellowship, Hematology and Medical Oncology, 2006 - 2009
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 2002 - 2006
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 2002

Certifications & Licensure

OR State Medical License 2005 - 2025
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2009 Sep 01
Terminated
Phase 1
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2011 Oct 01
Completed
Phase 2
Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Start of enrollment: 2012 May 11
Terminated
Phase 2
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies Start of enrollment: 2014 Mar 13
Completed
Phase 1, Phase 2
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma Start of enrollment: 2024 May 31
Not yet recruiting
Phase 1, Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

A phase II study of induction followed by intermittent duvelisib dosing in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Geoffrey Shouse, Lu Chen, Tanya Siddiqi, Alex Muir, Jennifer R Brown
Leukemia & Lymphoma. 2024-10-01
2 citations
Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study.
Laura Samples, Jenna Voutsinas, Bita Fakhri, Sirin Khajavian, Stephen Spurgeon
Blood Advances. 2024-05-14
Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma - The Oregon Health and Science University Experience.
Derek Galligan, Staci Williamson, Jessie Myers, Andy I Chen, Brandon Hayes-Lattin
Clinical Lymphoma, Myeloma & Leukemia. 2023-12-01

Abstracts/Posters

SYK Inhibitor Entospletinib in Combination with Obinutuzumab Demonstrates Efficacy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Stephen E Spurgeon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in CLL Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
TAK-243, a Small Molecule Inhibitor of Ubiquitin-Activating Enzyme (UAE), Induces ER Stress and Apoptosis in CLL Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018